- Home
- ENOV vs ETNB Comparison
ENOV vs ETNB Comparison
Compare ENOV & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENOV
- ETNB
- Stock Information
- Founded
- ENOV 1995
- ETNB 2018
- Country
- ENOV United States
- ETNB United States
- Employees
- ENOV N/A
- ETNB N/A
- Industry
- ENOV Fluid Controls
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- ENOV Industrials
- ETNB Health Care
- Exchange
- ENOV Nasdaq
- ETNB Nasdaq
- Market Cap
- ENOV 1.7B
- ETNB 1.5B
- IPO Year
- ENOV 2008
- ETNB 2019
- Fundamental
- Price
- ENOV $33.65
- ETNB $10.12
- Analyst Decision
- ENOV Strong Buy
- ETNB Strong Buy
- Analyst Count
- ENOV 5
- ETNB 8
- Target Price
- ENOV $58.00
- ETNB $26.43
- AVG Volume (30 Days)
- ENOV 1.6M
- ETNB 2.2M
- Earning Date
- ENOV 08-06-2025
- ETNB 08-04-2025
- Dividend Yield
- ENOV N/A
- ETNB N/A
- EPS Growth
- ENOV N/A
- ETNB N/A
- EPS
- ENOV N/A
- ETNB N/A
- Revenue
- ENOV $2,150,191,000.00
- ETNB N/A
- Revenue This Year
- ENOV $8.23
- ETNB N/A
- Revenue Next Year
- ENOV $6.18
- ETNB N/A
- P/E Ratio
- ENOV N/A
- ETNB N/A
- Revenue Growth
- ENOV 18.32
- ETNB N/A
- 52 Week Low
- ENOV $28.83
- ETNB $4.16
- 52 Week High
- ENOV $49.83
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- ENOV 56.27
- ETNB 58.34
- Support Level
- ENOV $30.84
- ETNB $9.45
- Resistance Level
- ENOV $33.95
- ETNB $10.34
- Average True Range (ATR)
- ENOV 1.15
- ETNB 0.52
- MACD
- ENOV 0.33
- ETNB -0.07
- Stochastic Oscillator
- ENOV 90.53
- ETNB 69.34
About ENOV Enovis Corporation
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).